#lecanemab — Public Fediverse posts

Lees tip -> Zorginstituut: lecanemab geen meerwaarde bij Alzheimer | Lecanemab vertraagt Alzheimer nauwelijks, kent risico’s en wordt daarom niet geadviseerd voor vergoeding. | #Alzheimer #basispakket #lecanemab #Leqembi #ZorginstituutNederland |

https://hbpmedia.nl/zorginstituut-lecanemab-geen-meerwaarde-bij-alzheimer/

quote :
厚生勞動省（相當於衛生福利部）專家小組8月21日審核通過 #日本 #衛采製藥 （ #Eisai ）與 #美國 藥廠 #百健（ #Biogen ）合作開發的 #阿茲海默症 新藥 #Lecanemab （又稱為 #Leqembi ）。日本厚生勞動大臣武見敬三今天正式批准這種新藥。

https://www.cna.com.tw/news/aopl/202309250285.aspx

Dilemma: Will Leqembi ™ prolong quality of life, or more suffering?

"When FDA approves a new cancer agent, oncologists usually ask: will it prolong duration of good quality life, or just prolong duration of suffering, and will the side effects profile be tolerable enough whether it works or not?

"Those kinds of questions seem pertinent to the new Alzheimer’s Disease (AD) medication, lecanemab, marketed now as Leqembi ™. "

#alzheimer #lecanemab #leqembi
https://caregivingoldguy.website/2023/08/07/dilemma-will-leqembi-tm-prolong-quality-of-life-or-more-suffering/

is it too skeptical of me to assume Lecanemab/leqembi by biogen/Eisai will show reduced brain volume for people on the drug (just like Phase 2 showed)? #lecanemab #leqembi

US-FDA grants accelerated approval for #lecanemab for patients with early #Alzheimers. The drug, to be sold as #Leqembi, will cost $26'000 per patient and year. "@US_FDA warns about brain swelling and bleeding on Lecamemab drug’s label, but imposes few restrictions on lecanemab’s use"

https://www.science.org/content/article/fda-approves-new-antibody-slow-alzheimer-s-disease-even-safety-concerns-linger?s=09

Breaking: #FDA approves Eisai-Biogen #Alzheimer's #ALZ drug #Leqembi, also known as #lecanemab: https://www.statnews.com/2023/01/06/fda-approves-alzheimers-drug-leqembi-eisai/